Acticor Biotech

Acticor Biotech EBIT Margin

Delisted

The EBIT Margin (Operating Margin) of Acticor Biotech (ALACT.PA) as of Nov 7, 2026 is -32.83 %. In the previous year, EBIT Margin (Operating Margin) was -21.05 % — a change of 55.98% (lower).

EBIT Margin

-32.83 %

YoY

55.98%

Last updated:

EBIT Margin (Operating Margin) of Acticor Biotech is 2018 -32.83 % . EBIT Margin (Operating Margin) of Acticor Biotech was 2017 -21.05 % . It decreases by 55.98% lower compared to the previous year.

Acticor Biotech's operating (EBIT) margin stands at -32.8%, down from 11.2% several years earlier.

The Acticor Biotech EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2011
0.23 EUR
Jan 1, 2012
0.20 EUR
Jan 1, 2013
0.15 EUR
Jan 1, 2014
11.21 EUR
Jan 1, 2015
-9.20 EUR
Jan 1, 2016
-0.71 EUR
Jan 1, 2017
-21.05 EUR
Jan 1, 2018
-32.83 EUR
The Acticor Biotech EBIT Margin history
YEAREBIT MarginYoY
-32.83 %+55.98%
-21.05 %+2,845.64%
-0.71 %-92.23%
-9.20 %-182.06%
11.21 %+7,261.77%
0.15 %-25.52%
0.20 %-10.35%
0.23 %+124.65%
0.10 %+278.65%
0.03 %-41.27%
0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Acticor Biotech Stock analysis

What does Acticor Biotech do? Acticor Biotech SA develops antithrombotic agents for acute thrombotic diseases, focusing on acute ischemic strokes and pulmonary embolisms. The company has one product, Glenzocimab, in Phase II clinical development, alongside pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN. It collaborates with partnering companies Ouest Valorisation, Genopole, Medicine, and Inserm for research and development. Acticor Biotech SAS is a clinical stage biopharmaceutical company spun off from INSERM, with 24 full-time employees. The firm generates revenue through its research and development activities, leveraging its partnership with INSERM and other institutions. Glenzocimab, its lead product, is in Phase II trials, indicating potential future licensing agreements or sales. The company's pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN represent additional revenue streams once they progress through clinical development. Acticor Biotech targets the biopharmaceutical sector, specifically focusing on thrombotic disease treatments. Its primary customers are pharmaceutical companies seeking to license or co-develop novel antithrombotic therapies. The company's partnerships with Ouest Valorisation, Genopole, Medicine, and Inserm facilitate its R&D efforts and potential commercialization pathways. Acticor Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acticor Biotech stock

EBIT Margin (Operating Margin) of Acticor Biotech is -32.83 % in 2018.

EBIT Margin (Operating Margin) of Acticor Biotech changed from -21.05 % to -32.83 %, representing a 55.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Acticor Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Acticor Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Acticor Biotech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Acticor Biotech